Stifel Raises Medivation Inc (MDVN) PT to $66 with Company In Play
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Sanofi Comments on Medivation's Rejection of Proposal
April 29, 2016 9:05 AM EDTSanofi Comments on Medivation's Rejection of Proposal
-Reiterates Commitment to Consummating Transaction-
Paris, France - April 29, 2016 - Sanofi  today commented on Medivation, Inc.'s (NASDAQ: MDVN) rejection of Sanofi's non-binding all-cash proposal to acquire Medivation for $52.50 per share:
Combining Sanofi and Medivation represents a compelling strategic and financial opportunity to drive immediate and certain value for Medivation's... More
Medivation's Board of Directors Unanimously Rejects Sanofi's Unsolicited Proposal
April 29, 2016 8:45 AM EDTSAN FRANCISCO, CAÂ -- (Marketwired) -- 04/29/16 -- Medivation, Inc. (NASDAQ: MDVN) today announced that its Board of Directors, after consultation with its financial and legal advisors, unanimously determined that the unsolicited proposal from Sanofi to acquire Medivation for $52.50 per share in cash substantially undervalues Medivation and is not in the best interests of the company and its stockholders.Â
"Over the past several years, we have established a world class oncology franchise and a unique, diversified and highly-promising late-stage development pipeline," said David Hung, M.D., Founder, President and Chief Executive Officer of... More
